Psychedelics firms are staking their claim in the biotech industry. The post Psychedelic Firms to Present at JP Morgan Healthcare Conference This Week...
MAPS Public Benefit Corporation (“MAPS PBC”), a company dedicated to transforming mental healthcare, announced an oversubscribed Series A financing....
Sexual abuse during psychedelic treatments continues to be a major issue within the industry. Sexual misconduct does happen during psychedelic treatments,...
–Recently announced positive Phase 2 topline data in Major Depressive Disorder (“MDD”) with 79% of patients in remission from depression after two...
If you’re interested in becoming a psychedelic therapist, deciding on how to train as one can be a bit of a minefield. There are now many...
The move marks a departure from the firm's previous reliance on philanthropic funding. The post Lykos Therapeutics Secures $100M in Series A Funding,...
The firm is targeting the FDA’s 505(b)(2) pathway for a potentially expedited approval process. The post Silo Pharma Proceeds with Ketamine Implant for...
The firm managed to find adequate research funding over the year as sale talks emerged. The post Tryp Therapeutics Lowers Losses in 2023; Sees New Era...
Microdose takes a look back at some of the top psychedelic stories of 2023. The post The Top Psychedelic Stories of 2023 appeared first on Microdose.
It has been quite a year – not just for the psychedelic industry, but also for humanity as a whole. Volatile might not be the most...